Healthcare Economics & Policy

Direct oral anticoagulants (DOACs) are on their way to surpassing warfarin as the anticoagulant of choice among Medicaid beneficiaries, despite their higher cost, according to new research published in the Journal of the American College of Cardiology.

It isn’t too late to sustain a 50-year-long reduction in cardiovascular disease-related deaths, according to research published in Clinical Cardiology—but with rising rates of obesity and diabetes, we’re closer than ever to reversing that progress.

People taking the widely prescribed blood-pressure medication valsartan may have been exposed to a probable human carcinogen for at least four years after a change in the manufacturing process introduced the impurity, according to an update from the FDA’s ongoing investigation into the contaminants that have been found in a series of angiotensin II receptor blockers (ARBs).

The FDA published its final guidance Jan. 22 for ensuring medical devices meet “more modern safety and performance criteria” before being cleared through the agency’s 510(k) review process.

The average annual cost of managing type 1 diabetes has skyrocketed, with the rising cost of insulin being a main contributor, according to a new issue brief from the Health Care Cost Institute.

A report from Persistence Marketing Research predicts the demand for neurovascular thrombectomy devices (NTDs), particularly stent retrievers, will surge in the near future alongside a growing prevalence of cerebral infarction and ischemic stroke.

Following a series of valsartan recalls over carcinogenic impurities, at least three sellers of the popular blood-pressure medication hiked their prices, the Wall Street Journal reported.

Interventional cardiologist Kipp Webb and representatives from Montana’s Bozeman Health Deaconess Hospital entered a 19-day jury trial Jan. 17 after Webb claimed the hospital created a monopoly over cardiology services in 2011, preventing him from practicing in the area.

Abbott plans to acquire Cephea Valve Technologies, a company developing a transcatheter mitral valve replacement (TMVR) device, the Chicago-area healthcare giant announced Jan. 16.

Copayment vouchers for P2Y12 inhibitors modestly improved the likelihood that patients would continue taking the guideline-recommended medications for one year after myocardial infarction, according to a study published in JAMA. However, patients supplied with this financial assistance didn’t see a subsequent improvement in clinical outcomes.

ST-segment elevation myocardial infarction (STEMI) survivors covered by Medicaid have lower rates of revascularization and higher rates of in-hospital mortality than their counterparts with private insurance, according to a study published in Circulation: Cardiovascular Quality and Outcomes.

High retail prices for diabetes test strips are driving a “gray market” in the U.S. as an increasing number of uninsured diabetics struggle to afford something they need as often as 10 times a day, the New York Times reports.